STOCK TITAN
  1. Home
  2. Sec-filings
  3. IRD
  4. [8-K] Opus Genetics, Inc. Reports Material Event

Opus Genetics (NASDAQ: IRD) outlines five IRD gene therapy programs and 2027 data

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Opus Genetics, Inc. reported on its expanding pipeline of gene therapies for inherited retinal diseases after hosting a Research and Development Science Forum. The company highlighted five IRD programs, with four clinical data readouts expected in 2027, and said RDH12, MERTK and RHO programs are expected to enter clinical testing over the next 12 to 18 months.

Management stated that its cash runway extends into 2029 and is expected to fund multiple clinical inflection points and potential product approvals, as well as opportunities for Priority Review Vouchers. Opus Genetics’ pipeline includes seven AAV-based programs, led by OPGx-LCA5 and OPGx-BEST1, targeting severe inherited retinal disorders.

Positive

  • None.

Negative

  • None.
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
IRD programs highlighted 5 programs Gene therapy programs targeting inherited retinal diseases
Clinical data readouts 4 readouts Expected in 2027 across IRD programs
Cash runway horizon into 2029 Funding multiple clinical inflection points and potential approvals
AAV-based programs 7 programs Total gene therapy pipeline, including LCA5 and BEST1
New programs entering clinical testing 3 programs RDH12, MERTK and RHO over next 12–18 months
inherited retinal diseases medical
"developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases"
Inherited retinal diseases are a group of genetic conditions in which errors in the genes that build and maintain the light-sensing cells at the back of the eye cause progressive vision loss or blindness; think of it as faulty wiring in a camera that gradually degrades the picture. They matter to investors because they define a clear patient population with high unmet need, driving demand for diagnostics and novel treatments (gene, cell or drug therapies) that can produce long-term revenue, regulatory milestones and intellectual property value.
Priority Review Vouchers regulatory
"potential product approvals and opportunities for Priority Review Vouchers"
A priority review voucher is an official token issued by a drug regulator that lets a company move a future drug application to the front of the review line, cutting the time regulators take to decide. It matters to investors because the voucher is often transferable or sellable and can be worth hundreds of millions, acting like a "fast-pass" that speeds a product to market or becomes a one-time cash asset on a company’s balance sheet.
Orphan Drug exclusivity regulatory
"the potential for Orphan Drug exclusivity and Priority Review Vouchers"
A regulatory right that gives a drugmaker sole approval to market a medicine for a specific rare disease for a set number of years, during which the regulator will not approve the same medicine from competitors for that same use. For investors, this is like a temporary exclusive sales permit that can protect revenue and justify higher valuation because it reduces near‑term competition and helps the company recover development costs and capture market share.
AAV-based programs medical
"The Company’s pipeline includes seven AAV-based programs, led by OPGx-LCA5"
forward-looking statements regulatory
"This press release contains certain statements that are not statements of historical fact and are forward-looking statements"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 16, 2026

Opus Genetics, Inc.
(Exact name of registrant as specified in its charter)

Delaware
001-34079
11-3516358
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)

8 Davis Drive
Durham, NC
27713
(Address of principal executive offices)
(Zip Code)

(984) 884-6030
(Registrant’s telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.0001 par value per share
IRD
The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
Item 7.01
Regulation FD Disclosure.

On June 16, 2026, Opus Genetics, Inc., a Delaware corporation (the “Company”), issued a press release entitled “Opus Genetics Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal Diseases.” A copy of the press release is furnished herewith as Exhibit 99.1.

The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall such information be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such a filing. The Company undertakes no obligation to update, supplement, or amend the materials attached hereto as Exhibit 99.1.

Item 9.01
Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.
Description
99.1
Press Release, dated June 16, 2026.
104.1
Cover Page Interactive Data File (embedded within Inline XBRL document).
 
SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
OPUS GENETICS, INC.
     
Date: June 16, 2026
By:
/s/ Dr. George Magrath
 
Name:
Dr. George Magrath
 
Title:
Chief Executive Officer


Exhibit 99.1

Opus Genetics Highlights Five Gene Therapy Programs Targeting
Significant Unmet Need in Patients with Inherited Retinal Diseases

Rapidly Advancing Five IRD Programs​ with Four Clinical Data Readouts Expected in 2027
 
RDH12, MERTK and RHO Programs Expected to Enter Clinical Testing over the Next 12 to 18 Months
 
Cash Runway into 2029 Expected to Fund Multiple Clinical Inflection Points, Potential Product Approvals and Opportunities for Priority Review Vouchers
 
IRD Prevalence Across Select Global Markets Provides a Significant Commercial Opportunity Across Opus Genetics’ Pipeline
 
RESEARCH TRIANGLE PARK, N.C. – June 16, 2026 - Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), hosted a Research and Development (R&D) Science Forum where management and leading IRD experts highlighted the Company’s expanding gene therapy pipeline for severe retinal diseases. The event highlighted three new programs entering clinical testing, recent LCA5 and BEST1 clinical data, the global IRD market opportunity, and clinical development and execution strategies.
 
“As featured in our R&D Science Forum, our validated scientific approach and early clinical success provides strong momentum as we expand into our new set of promising programs,” said George Magrath, M.D., Chief Executive Officer of Opus Genetics. “We have first‑mover advantage across multiple indications, supported by broad intellectual property protection, rare‑disease regulatory pathways that may offer flexibility and accelerated approval, and the potential for Orphan Drug exclusivity and Priority Review Vouchers. Our approach emphasizes streamlined timelines, capital‑efficient development, a premier collection of scientific advisors, and an experienced leadership team capable of executing multiple clinical programs in parallel.”
 
A replay of the event and copy of the slide presentation may be accessed on Opus Genetics’ website under the Investors section: Events.

Gene Therapy Program Highlights

OPGx-RDH12
•
RDH12 mutations cause a severe form of Leber congenital amaurosis (LCA), which leads to early, rapid vision loss in infancy or childhood, often resulting in legal blindness before the third decade of life.
•
Estimated global prevalence is 30,900 patients, including 2,500 patients in the U.S. and 17,500 patients in the Middle East / North Africa.*
•
OPGx-RDH12 is designed to restore a key component of the visual cycle.
•
In preclinical studies, OPGx-RDH12 delivered a functional RDH12 enzyme in vivo and restored structure and function in a small animal model.
•
This program is expected to initiate clinical testing in the U.S. in the fourth quarter of 2026. Funding is supported by the RDH12 Alliance.

OPGx-MERTK
•
MERTK mutations cause a severe form of autosomal recessive retinitis pigmentosa, which has an early-onset (childhood or adolescence) and results in rapid vision loss.
•
Estimated global prevalence is 21,960 patients, including 2,600 patients in the U.S. and 14,300 patients in the Middle East / North Africa.*
•
OPGx-MERTK is designed to restore critical retinal pigment epithelium metabolic functions.
•
In preclinical studies, OPGx-MERTK provided evidence of retinal preservation of structure/ function and preserved outer nuclear layer thickness in a small animal model of retinal degeneration.
•
This program is expected to initiate clinical testing at the Cleveland Clinic Abu Dhabi in the first quarter of 2027. Funding is supported by a consortium led by Abu Dhabi’s Healthcare Research and Innovation Fund.

OPGx-RHO
•
RHO mutations cause autosomal-dominant retinitis pigmentosa, a highly variable, often slowly progressive rod-cone dystrophy characterized by misfolded or dysfunctional rhodopsin that drives photoreceptor stress and progressive peripheral field loss followed by central vision decline.
•
Estimated global prevalence is 30,200 patients, including 8,800 patients in the U.S.*
•
OPGx-RHO is designed to “silence and replace” in autosomal dominant RHO.
•
In preclinical studies, OPGx-MERTK maintained rod morphology in the retinas in two large animal models.
•
This program is expected to initiate clinical testing globally in the second half of 2027.

OPGx-LCA5
•
LCA5 mutations cause a very early onset, severe disease typically presenting in infancy or early childhood.
•
Estimated global prevalence is 3,240 patients, including 170 patients in the U.S.*
•
OPGx-LCA5 is designed to restore the lack of functioning lebercilin, a key protein of the visual cycle, which severely impairs photoreceptor function.
•
In the ongoing Phase 1/2 clinical trial, visual acuity was improved and maintained in the adult cohort over 24 months and improved in the pediatric cohort over 6 months. In addition, the full-field stimulus test (FST) demonstrated durable vision improvement and microperimetry data provided evidence of increased sensitivity and movement of fixation toward the fovea.
•
Recruitment is ongoing in the run-in period for the pivotal Phase 3 trial. In parallel, the clinical and commercial batch of drug product is being manufactured. Dosing with OPGx-LCA5 is expected to start in the fourth quarter of 2026.

OPGx-BEST1
•
BEST1 mutations disrupt cellular ion and fluid homeostasis resulting in electrophysiological abnormalities, RPE dysfunction, and retinal degeneration, with a range of onset from childhood to adulthood and a slow rate of progression.
•
Estimated global prevalence is 21,800 patients, including 8,400 patients in the U.S. comprised of approximately 8,000 best vitelliform macular dystrophy (BVMD) and approximately 400 autosomal recessive bestrophinopathy (ARB).*
•
OPGx-BEST1 is designed to target retinal pigment epithelium (RPE) cells and restore bestrophin function.
•
In the ongoing Phase 1/2 clinical trial, three BVMD and two ARB participants were enrolled in the first cohort, with dosing completed in May 2026.
•
Three-month topline data from Cohort 1 is expected in September 2026.

Commercial Market Opportunity
•
IRD patient prevalence across select global markets provides significant commercial market opportunity across Opus’ pipeline.
•
IRD prevalence may be higher than current estimates in some mutations. For example, patients may not undergo genetic testing when clinicians diagnose BEST1 disease based on the presence of a characteristic vitelliform (“egg-yolk”) lesion beneath the macula.

* Triangle Insights Analysis of 5 Key Markets, 2026

About Opus Genetics
 
Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The Company is developing durable, one-time treatments designed to address the underlying genetic causes of severe retinal disorders. The Company’s pipeline includes seven AAV-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RDH12, MERTK, RHO, CNGB1 and NMNAT1. The Company is based in Research Triangle Park, NC. For more information, visit www.opusgtx.com.

Forward-Looking Statements
 
This press release contains certain statements that are not statements of historical fact and are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements related to cash runway and future financing availability, potential product approvals, and Priority Review Voucher opportunities, the clinical development, clinical results, preclinical data and future plans for OPGx-LCA5, OPGx-BEST1, OPGx-MERTK, OPGx-RDH12, OPGx-RHO and earlier stage programs, and expectations regarding us, our business prospects and our results of operations, and are subject to certain risks and uncertainties posed by many factors and events that could cause our actual business, prospects and results of operations to differ materially from those anticipated by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those described under the heading “Risk Factors” included in our most recent Annual Report on Form 10-K for the year ended December 31, 2025 and in our other filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. These forward-looking statements are based upon our current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “aim,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. We undertake no obligation to publicly update any forward-looking statements in order to reflect events or circumstances that might subsequently arise.

Contacts:
 
Investors
Jenny Kobin
Remy Bernarda
IR Advisory Solutions
ir@opusgtx.com
 
Media
 
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com
 

Source: View Original Filing on SEC EDGAR

FAQ

What did Opus Genetics (IRD) announce about its gene therapy pipeline?

Opus Genetics highlighted an expanding pipeline of gene therapies for inherited retinal diseases, including five IRD programs. The update followed an R&D Science Forum where management and external experts discussed new clinical programs, recent LCA5 and BEST1 data, and development strategies.

How many clinical data readouts did Opus Genetics (IRD) say to expect in 2027?

The company stated that four clinical data readouts are expected in 2027 across its inherited retinal disease programs. These readouts are positioned as important clinical inflection points as Opus advances its gene therapy candidates through early and mid-stage development.

Which Opus Genetics (IRD) programs are expected to enter clinical testing soon?

Opus Genetics indicated that its RDH12, MERTK and RHO programs are expected to enter clinical testing over the next 12 to 18 months. These candidates expand the company’s focus beyond its existing LCA5 and BEST1 gene therapy programs for severe retinal disorders.

What cash runway guidance did Opus Genetics (IRD) provide?

The company said its cash runway extends into 2029. Management indicated this funding horizon is expected to support multiple clinical inflection points, potential product approvals, and possible opportunities to obtain Priority Review Vouchers within its inherited retinal disease gene therapy portfolio.

How many AAV-based programs are in Opus Genetics’ (IRD) pipeline?

Opus Genetics reported a pipeline of seven AAV-based gene therapy programs. The lead candidates are OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional programs targeting RDH12, MERTK, RHO, CNGB1 and NMNAT1.

What strategic advantages did Opus Genetics (IRD) highlight for its IRD programs?

The company emphasized first-mover advantage in multiple indications, broad intellectual property protection, and use of rare-disease regulatory pathways. It also cited potential Orphan Drug exclusivity and Priority Review Vouchers, alongside capital-efficient development and an experienced team running several programs in parallel.

Filing Exhibits & Attachments

4 documents

Press Releases

Other Documents